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Summary 
This study was undertaken to determine whether acute phase proteins (APP) induce the synthesis 
of interleukin 1/8 (IL-1/8) and its specific antagonist, IL-1 receptor antagonist (IL-1Ra), in human 
peripheral blood mononuclear cells (PBMC). PBMC from healthy volunteers were incubated 
with C-reactive protein (CRP), oq-antitrypsin (ott-AT), or ott-add glycoprotein (AGP), and the 
levels of IL-1/8 and IL-1Ra produced were measured by specific radioimmunoassay. To evaluate 
the effects of c~t-AT further, a synthetic pentapeptide FVYLI corresponding to the minimal 
binding sequence for the serpine--enzyme complex receptor was also evaluated. PBMC incubated 
for 24 h with CRP, c~t-AT, or the pentapeptide FVYLI synthesized large quantities of IL-1Ra, 
5-10-fold greater than the amount of IL-1B produced by these cells. AGP induced significantly 
less IL-1Ra than the other APP tested. These effects were shown to be specific, in that polyclonal 
antibodies against CRP, c~I-AT, and AGP eliminated the cytokine production induced by these 
respective proteins. CRP, c~vAT, FVYLI, and AGP were synergistic with low concentrations 
of endotoxin in the induction of both IL-1Ra and IL-1/8 synthesis. We suggest that the preferential 
induction of IL-1Ra by APP may contribute to their antiinflammatory effects and provide an 
important regulatory sigrial for the acute phase response. 
T 
he liver is thought to play a central role in limiting local 
and systemic inflammation. D-Galactosamine,  an hepa- 
tocyte-specific inhibitor of RNA and protein synthesis, sen- 
sitizes animals to the lethal effects of endotoxin or TNF-ot, 
suggesting that proteins synthesized in the liver in response 
to inflammatory mediators attenuate their biological effects 
(1). The acute phase response induced by turpentine adminis- 
tration protects mice from D-galactosamine/endotoxin and 
D-galactosamine/TNF-cr-induced death (2). 
In some instances,  specific hepatic acute phase proteins 
(APP) 1 synthesized in response to infection or tissue injury 
have been demonstrated to protect animals from various inflam- 
matory insults. For example, transgenic mice expressing rabbit 
C-reactive protein (CRP) resist endotoxemia (3). Rabbits with 
elevated serum CRP induced by croton oil injections exhibit 
diminished neutrophil infiltration and vascular permeability 
in a C5a-induced alveolitis model (4). Serum amyloid A at- 
tenuates IL-1- and TNF-ot-induced fever and hypothalamic 
I Abbreviations used in this paper: AGP, c~t-acid glycoprotein;  APP, acute 
phase protein(s);  oq-AT, oq-antitrypsin;  CRP, C-reactive  protein; IL-2Ra, 
IL-2 receptor antagonist; SEC, serpine-enzyme  complex. 
PGE2 synthesis in mice (5). Both C~l-antitrypsin (oq-AT) and 
antichymotrypsin inhibit neutrophil superoxide production 
(6, 7), which may contribute to the protective effect of otl- 
AT on the development of bleomycin-induced pulmonary 
fibrosis (8). Furthermore otl-AT protects cultured lung en- 
dothelial cells from endotoxin injury (9). The mechanisms 
by which APP protect against inflammation are generally not 
understood. 
IL-1 plays a key role in inflammatory and growth processes. 
IL-1 is an important mediator of fever, hypotension, and the 
acute phase reaction (10). A specific inhibitor of IL-1 has been 
identified and its cDNA has been cloned (11-13). This inhib- 
itor is closely related to IL-lot and IL-1/8 and competitively 
blocks the binding of IL-1 to its receptors (12, 13). This ILl 
receptor antagonist (IL-1Ra) has no agonist activity (14) and 
efficiently blocks IL-1 effects both in vitro and in vivo (12, 
13). IL-1Ra has been shown to reduce the severity of sepsis, 
arthritis, colitis, and other inflammatory processes in several 
animal models (12, 13). 
In this investigation, we sought to determine whether or 
not the antiinflammatory effects of certain hepatic APP could 
be attributed to a modulation in the profile of cytokines pro- 
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cytokine antagonists. 
Materials  and Methods 
Reagents.  Purified  human otracid glycoprotein (AGP), Otl-AT, 
human leukocyte elastase, LPS from Escherichia coli (055:B5), goat 
and rabbit IgG, DMSO, and polyethylene glycol of 8,000 mol wt 
were purchased from Sigma Chemical Co. (St. Louis, MO). Rabbit 
polyclonal  anti-human AGP and anti-human al-AT IgG were also 
obtained from Sigma Chemical Co. A polyclonal  goat anti-human 
CRP IgG was purchased from BIODESIGN Int. (Kennebunkport, 
ME). IL-2  was provided  by Cetus/Chiron (Emeryville,  CA). A neu- 
tralizing rabbit IgG against  human IL-2  and an anti-p75 ID2 receptor 
mAb were gifts from Endogen Inc. (Boston, MA). Polymyxin B 
sulfate was purchased from Pfizer Inc. (New York). 
al-AT--elastase complexes were prepared according to previously 
described methods by incubating equimolar concentrations of cq- 
AT and elastase at 37~  for 15 rain (15). The peptides FVYL and 
FVYLI (provided  from M. Berne, Department of  Physiology,  Tufts 
University School of  Medicine, Boston) were synthesized by solid- 
phase method and then HPLC purified. Both peptides were dis- 
solved in DMSO before use. CRP was isolated from serum of 
patients  treated with high-dose Ib2  using phosphorylcholine- 
Sepharose affinity  chromatography (16). SDS-PAGE of the purified 
material revealed a single protein band. The LPS content of the 
various protein and peptide preparations used in these studies was 
determined by a Limulus amebocyte  lysate  assay  (Associates  of Cape 
Cod, Inc., Woods Hole, MA). CR.P and FVYLI stock solutions 
were negative (<10 pg/ml) in these assays. The LPS content of the 
AGP and arAT preparations varied but was <10 pg/ml at the di- 
lutions used in the LPS synergy studies described in Results. 
PBMC Cultures.  PBMC were isolated from the heparinized 
blood of healthy donors by centrifugation through FicoU  Hypaque 
(Sigma Chemical Co.). The cells were washed three times with 
sterile PBS and then incubated in polypropylene tubes (5 ml) at 
a density of 2.5  x  106 cells/ml in 1 ml of RPMI 1640 medium 
(GIBCO, Grand Island, NY), containing 10 mM Hepes (Sigma 
Chemical Co.), 2 mM t-glutamine, 100 U/ml penicillin, and 100 
/xg/ml streptomycin (Irvine Scientific, Santa Ana, CA). Complete 
medium was subjected to ultraftltration to remove endotoxin and 
other cytokine-inducing  materials (17). Polymyxin  B (5/xg/ml) was 
included in all culture medium except that used in experiments 
with LPS. PBMC were  incubated with CR.P, cq-AT, FVYL, 
FVYLI, AGE or LPS at 37~  in a humidified atmosphere con- 
taining 5% CO2 for 24 h unless stated otherwise. PBMC cultures 
were frozen and thawed three times (18). The amount of IL-I~ 
and IIr  reported in these experiments therefore represents the 
total amount (secreted plus cell-associated) generated. 
RIAs.  Specific  RIAs for IL-1Rc~ and IL-1B were used in each 
study (18, 19). The threshold of detection for both assays  was 80-160 
pg/ml. 
Statistics.  All data are expressed as mean  +  SEM. Two-tailed 
paired t tests and analysis  of variance (ANOVA) using Fisher's least 
significant difference were used. P values <0.05 were considered 
to be significant. 
of as low as 50/xg/ml CRP induced significantly more IL- 
1Ra (1.9  _+  0.3 ng/ml) than did control medium (0.35  +_ 
0.1 ng/ml) (P <0.05). Induction of IL-1Ra by CRP was con- 
centration dependent and maximal at 300/~g/ml CRP.  In 
contrast, CRP induced IL-lfl only at the highest concentra- 
tion tested (300 lzg/ml) (P <0.05). The amount of IL-1Ra 
produced by PBMC at a CRP concentration of 300/xg/ml 
was nearly 10-fold  the amount of IL-1B produced. 
We next studied the time course of IL-1Ra and IL-I~ 
production in response to CRP. A concentration of 300/zg/ml 
CRP was used in these experiments. Freshly isolated PBMC 
contained neither measurable IL-1Ra nor IL-1/3. After a 2-h 
incubation, low levels of IL-1Ra were detectable.  Significant 
amounts of IL-1Ra (1.4 +  0.20 ng/ml) were measurable after 
a 4 h incubation and peak levels oflL-1Ra (11.8 _+  1.2 ng/ml) 
and IL-1B (1.5 + 0.23 ng/ml) were obtained after 24 h (Fig. 2). 
To rule out the possibility that the effects observed  with 
CRP were due to endotoxin contamination, PBMC were in- 
cubated with CRP in the presence or absence of an anti-CRP 
antibody or polymyxin B. As shown in Table 1, anti-CRP 
antibodies, but not control antibodies, completely blocked 
CRP-induced IL-1Ra and IL-1[3  synthesis, whereas LPC- 
induced IL-1Ra and IL-1B production was not affected. In 
parallel experiments, polymyxin B (5/~g/ml) completely abol- 
ished LPS-induced but not CRP-induced cytokine produc- 
tion (Table 1). 
IL-2 induces both IL-I~ and IL-1Ra in vitro (20, H. Tilg, 
manuscript submitted for publication).  Because the CRP used 
in our studies was purified from sera obtained from patients 
undergoing IL-2 treatment, it was essential to demonstrate 
that our CRP preparation did not contain residual IL-2, which 
could contribute to the IL-1Ra and IL-1/~ production attrib- 
uted to CRP. PBMC stimulated with IL-2 or CkP were in- 
cubated with an anti-IL-2 or anti-p75 IL-2 receptor IgG and 
the production of IL-1Ra and IL-I~ measured. Both anti- 
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Results 
Induction of lL-1Ra and IL-lfl Synthesis in Human PBMC 
by CRP.  The induction of IL-1Ra and IL-1/~ by CRP after 
a 24-h incubation period is shown in Fig. 1. A concentration 
CRP  (pg/ml) 
Figure  1.  Induction  of IL-1Ra (open bars) and IL-I~ (hatched bars) by 
human PBMC from six donors incubated  with increasing  concentrations 
of CRP. Data are shown as mean + SEM. *P <0.05; **P <0.005 com- 
pared to unstimulated  PBMC. 
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Figure  2.  Time course of IL-1Ra (open bars) and IL-1/~ (hatched  bars) 
production by PBMC stimulated with 300 ktg/ml CRP. Data are derived 
from the cells of three donors and are shown as mean •  SEM. *P <0.05; 
￿9  *P <0.005  from t  ~  0. 
bodies completely suppressed IL-2-induced IL-1Ra and IL- 
1/3 production but did not  influence CRP-induced  IL-1Ra 
and  IL-13  synthesis  (Table  1). 
Induction of IL-IRa  and IL-113 in PBMC  by crl-AT and 
FVYLI.  Both  Oil-AT and FVYLI induced  concentration- 
dependent  IL-1Ra and IL-13 synthesis (Fig.  3).  oq-AT at a 
concentration of 10- 7 M  induced significant amounts of IL- 
1Ra (1.9  _+  0.2 ng/ml), whereas IL-13 production required 
a  higher  concentration  (10 -6 M)  of o~I-AT (Fig.  3  A).  At 
o~I-AT concentrations  of 10-6 and 10-5 M, the induced IL- 
1Ra concentrations  were approximately eightfold  those  of 
IL-13.  The effects of oerAT on IL-1Ra and IL-13 produc- 
tion were almost completely blocked by a specific anti-oct- 
AT antibody that had no effect on LPS-induced cytokine syn- 
thesis  (Table 2).  Despite  the  fact  that  c~I-AT is  known  to 
bind to the serpin-enzyme complex (SEC) receptor on human 
monocytes as a complex with elastase (21),  the addition  of 
leukocyte  elastase did  not  enhance  the  inductive  effects of 
otl-AT.  In fact,  incubation  of PBMC  with  equimolar  con- 
centrations of elastase and c~I-AT induced IL-1Ra and IL-13 
levels identical to those obtained with aq-AT alone (data not 
shown). 
The synthetic pentapeptide FVYLI, the minimal binding 
sequence  for  the  SEC  receptor  (22),  showed  a  pattern  of 
cytokine induction  similar to that  of c,I-AT.  At  a concen- 
tration of 10 -6 M, significant amounts of IL-1Ra (1.6  +  0.3 
ng/ml) were induced, whereas significant IL-13 production 
was observed only at 10 -4 M  (Fig. 3 B).  10 -4 M  of FVYLI 
induced  as much  IL-1Ra and  IL-3 as  10 -6 M  col-AT.  The 
ratio of IL-IRa to IL-13 was consistently in excess of 5 with 
each concentration FVYLI tested over 10 -6 M. The control 
peptide FVYL showed no significant induction  of both IL- 
Table  1.  Neutralization of CRP-induced Cytokine Synthesis with Specific Antibodies 
Stimulus  Inhibitor  IL-1Ra  IL-13 
ng/ml 
CRP  (100/zg/ml)  -  7.7  _+  1.1  0.9  _+  0.1 
Control  IgG  7.4  +  1.2  0.8  _+ 0.2 
anti-CRP  0.5  +  0.1"  0.1  -+ 0.05* 
LPS (100  ng/ml)  -  8.5  +  1.1  7.4  _+  1.2 
Control  IgG  8.0  _+  0.9  6.9  _+  1.2 
anti-CRP  8.3  _+  1.0  7.2  _+  1.1 
LPS (100  ng/ml)  --  8.5  •  1.1  7.4  +  1.2 
PMB  0.3  +  0.1"  0.2  _+  0.1" 
CKP  (100/zg/ml)  -  8.1  +  1.4  1.0  +  0.1 
PMB  7.9  +  1.3  0.9  +  0.2 
IL-2 (1,000  U/ml)  -  7.3  +  1.4  5.5  +  1.2 
anti-p75  0.5  _+  0.1"  0.3  _+  0.1" 
anti-IL-2  0.4  _+  0.1"  0.2  _+  0.1" 
CRP  (100/zg/ml)  -  8.2  +  1.4  0.9  +  0.2 
anti-p75  8.1  _+  1.3  1.0  +  0.2 
anti-IL-2  7.9  +  1.2  1.1  +  0.2 
PBMC were incubated for 24 h. Data represent mean  •  SEM from three experiments. Polymyxin B was used at a concentration of 5/zg/ml. The 
goat anti-CR.P antibody and a nonimmune goat IgG were both used at a concentration of 100 #g/ml. The anti-IL-2 antiserum and anti-p75  IL-2 
receptor mAb were used at concentrations of 1,000 U/ml and 100/~g/ml,  respectively. 
* P <0.005  from CRP, IL-2, and LPS alone. 
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Figure 3.  (A) Induction  of IL-1Ra (open bars) and Ibl/~ (hatched bars) 
by human PBMC incubated with r  (mean _+  SEM; n =  6).  *P 
<0.05; **P <0.005 compared to unstimulated  PBMC. (B) Induction  of 
IL-1Ra (wen bars) and Ibl/3 (hatched bars) by the pentapeptide  FVYLI  in 
human PBMC (same donors as A) (mean + SEM; n = 6). *P <0.05; 
**P <0.005 compared to unstimulated  PBMC. 
1Ra and IL-13; likewise, DMSO at the concentrations used 
for dissolving the short  peptides did not induce cytokine 
production (data not shown). 
Induction of lL-1Ra and IL-lfl by AGP.  We also tested an- 
other APE AGP, for its potential to induce IL-1Ra and IL- 
13. AGP induced significantly less IL-1Ra than CRP or Otr 
AT (Fig. 4).  In addition, the ratio of IL-1Ra to IL-I~ was 
only 2.4:1. AGP-induced cytokine production was abrogated 
with a specific antibody, whereas a control antibody showed 
no effect (Table 2). The anti-AGP IgG had no effect on LPS- 
induced IL-1Ra or IL-1B synthesis. 
Synergistic Effects of CRP and cerAT on the Synthesis of lL- 
IRa by PBMC.  PBMC from three donors were incubated 
8- 
6- 
E 
4' 
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Figure 4. 
0  1  10  50  100  300  1000 
AGP  (pg/ml) 
Induction of IL-1Ra (open bars) and IL-I~ (hatched bars) by 
PBMC incubated  with AGP (mean +_ SEM; n = 4). *P <0.05; **P <0.005 
compared to unstimulated  PBMC. 
with increasing concentrations of CRP and at-AT for 24 h, 
and the IL-1Ra produced was measured by RIA. Low con- 
centrations of CRP and at-AT, which individually induced 
only modest amounts of IL-1Ra, were highly stimulatory 
when present simultaneously (Table 3). This synergy was es- 
pecially  evident with 10 -7 M  oq-AT, which induced only 
0.93  _  0.03 ng/ml IL-1Ra by itself but 3.27  +  0.35 ng/ml 
IL-1Ra (P <0.02) in the presence of trivial (10/xg/ml) con- 
centrations of CRP. 
Synergistic Effects of CRP, a1-AT,  FVYLI,  and AGP with 
LPS on IL-1Ra and IL-lfl Synthesis by PBMC.  PBMC were 
incubated with increasing concentrations of LPS and either 
50/zg/ml CRP,  10 -7  M  otrAT,  10 -6 M  FVYLI, or  100 
/xg/ml AGE LPS induced comparable amounts of IL-1Ra and 
IL-1/~ (Figs. 5 and 6). Each APP tested as well as the peptide 
FVYLI were synergistic with low concentrations (10 pg/ml) 
of LPS in the induction of IL-1Ra (Fig.  5) and IL-1/~/(Fig. 
6). PBMC incubated with LPS (10 pg/ml) plus APP synthe- 
sized significantly more IL-1Ra and IL-I~ than with LPS 
alone (P <0.001 for each APP tested). DMSO at concentra- 
tions used to dissolve FVYLI had no effect on LPS-induced 
IL-1Ra and IL-1B  synthesis (data  not shown). 
Discussion 
Several hepatic APP have been shown to either induce or 
augment the synthesis of IL-1, TNF, and IL-6 in vitro (23-25), 
suggesting that APP contribute to the development of an 
inflammatory response.  Despite these in vitro data, several 
animal models exist in which the prior initiation of an acute 
phase response  or the administration of a specific APP have 
been shown to limit the severity of inflammation or to pro- 
tect against the lethal effects of LPS, TNF, or IL-1 (2-9). 
The mechanism underlying these antiinflammatory effects 
is unclear. 
1632  Interleukin  1 Receptor Antagonist Induction  by Acute Phase Proteins Table  2.  Effect of Specific Antibodies on cr,-AT-  and AGP-induced IL-IRa and IL-I~ Synthesis 
Stimulus  Antibody  IL-1B  IL-1R.a 
oq-AT (10 -6 M) 
LPS  (100 ng/ml) 
AGP (300/~g/ml) 
LPS (100  ng/ml) 
ng/ml 
--  8.7  _+  1.4  1.4  +  0.4 
Control IgG  8.3  +_  1.2  1.3  _+  0.3 
c~vAT  1.9  _+  0.2*  0.3  -+  0.1" 
--  8.5  _+  1.1  7.4  _+  1.2 
Control IgG  8.6  _+  1.4  7.0  _+  0.8 
otvAT  7.9  _+  1.0  7.3  _+  0.9 
-  1.8  _+  0.4  0.4  +  0.2 
Control IgG  1.9  _+  0.3  0.5  _+  0.2 
AGP  0.3  _+  0.1"  0.2  _+  0.1 
-  8.5  _+  1.1  7.4  _+  1.2 
Control lgG  8.7  _+  1.0  8.1  +  0.9 
AGP  9.0  _+  0.9  8.3  _+  1.2 
PBMC were incubated for 24 h. Data represent mean  _+  SEM from three experiments. Rabbit anti-~vAT and AGP antibodies as well as nonim- 
mune IgG were used diluted  1/100. 
" P <0.005  from c~I-AT and AGP alone. 
CR,  P  has been  shown  to induce the synthesis of IL-lot, 
IL-I~, TNFot, and IL-6 in human PBMC and alveolar mac- 
rophages (23,  24),  suggesting that one of its primary func- 
tions is the amplification of inflammatory responses. How- 
ever, our studies demonstrate that CRP  is, in fact, a more 
potent inducer of the antagonist IL-1Ra. In this respect, the 
synthetic response to CRP  more closely resembles the re- 
sponse to immune  complexes or aggregated IgG than  the 
response to LPS or IL-2, both of which induce approximately 
equal amounts of IL-1Ra and IL-I~/(Table 1).  The conten- 
Table  3.  Synergistic Effects of CRP and oil-AT on the Synthesis of lL-1Ra  by PBMC 
CRP 
oil-AT 
0  10 .9  10 -s  10 -7  10 -6 
IL-Ra 
~g/mt 
Exp.  1  0 
1 
10 
100 
Exp.  2  0 
1 
10 
100 
Exp.  3  0 
1 
10 
100 
ng/ml 
0.21  0.24  0.32  0.88  4.7 
0.22  0.38  0.32  1.2"  3.5 
0.49  0.3  0.41  2.7*  5.7* 
4.4  4.8  5.9*  9.2*  8.7 
0.38  0.37  0.52  0.99  5.2 
0.42  0.26  0.45  1.3  4.6 
0.51  0.63  1.6"  3.2*  7.8* 
3.6  3.2  4.8*  8.9*  7.9 
0.27  0.21  0.26  0.93  4.4 
0.33  0.27  0.32  1.6"  4.5 
0.48  0.59  0.69  3.9*  8.2* 
3.8  3.6  6.1"  9.7*  8.9* 
*  IL-1Ra values greater than  the sum of those achieved with CRP and aq-AT individually. 
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Figure 5.  Effects  of (A) CRP (50/~g/ml), (B) cq-AT (10-7 M),  (C) 
FVYLI (10 -6 M), and (D) AGP (100/~g/ml)  on LPS-induced synthesis 
of IL-1Ra by human PBMC (O, LPS alone; O, LPS + APP). One repre- 
sentative experiment  from three performed is shown. 
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Figure  6.  Effects  of (A) CRP (50/~g/ml), (B) oq-AT (10 -7 M),  (C) 
FVYLI (10 -6 M),  and (D) AGP (100 ~r  on LPS-induced synthesis 
of IblB by human PBMC (same donors as in Fig. 5) (O, LPS alone; 0, 
LPS  +  APP).  One representative experiment  from three is shown. 
tion that CRP is primarily an antiinflammatory mediator is 
supported by data from animal studies in which high serum 
levels of CRP resulting either from prior turpentine treat- 
ment or as a result of the expression of a transgene protect 
mice from lethal doses of LPS (2, 3). The morbidity associated 
with  sepsis is  thought to  be due to endogenous platelet- 
activating factor, a phosphorylcholine-containing phospho- 
lipid (26).  As suggested by Xia et al.  (3,  27),  the binding 
of platelet-activating factor through its phosphorylcholine 
moiety may indeed be an important mechanism underlying 
the protective effect of CRP.  However, several studies have 
shown that IL-1Ra exerts a similar protective effect in LPS- 
treated animals and it is therefore equally plausible that the 
induction of IL-1Ra is the primary mechanism by which CRP 
mediates its protective effects (12,  13,  28). 
The hepatic APP 0/1-AT is a member of the serine pro- 
tease inhibitor (serpin) family. 0/1-AT is, in fact, the major 
circulating inhibitor of neutrophil elastase and a deficiency 
of this inhibitor is associated  with chronic inflammation in 
the lung and liver with premature emphysema and cirrhosis 
(29).  0/1-AT-elastase complexes are known to bind to SEC 
receptors present on hepatocytes, the result of which is the 
up-regulation of 0/1-AT synthesis in the liver (21). A similar 
receptor has been described on neutrophils and its engage- 
ment results in chemotaxis (30). We have shown that stimu- 
lation of PBMC  with prepared 0/1-AT-elastase complexes, 
0/1-AT alone, or the pentapeptide FVYLI induces the pre- 
ferential synthesis of IL-1Ra, presumably a result of signaling 
through the SEC receptor or a related structure. The activity of 
0/1-AT in the absence of exogenous elastase is most likely due 
to the formation of a complex with endogenous elastase (31). 
SEC receptors are involved in the clearance of several dis- 
tinct SECs including thrombin-antithrombin III, thrombin- 
heparin  cofactor II,  as  well  as  0/1-AT-elastase  (32).  Our 
results suggest that SEC receptors not only remove endoge- 
nous proteases such as elastase from the circulation but may 
trigger the generation of an important IL-1 antagonist. The 
development of pulmonary fibrosis in response to the chemo- 
therapeutic agent bleomycin is largely due to endogenous IL-1 
and can be prevented by the administration of IL-1Ra or o/l- 
AT (8, 33). The role of IL-1 in tissue fibrosis and the ability 
of SECs to stimulate IL-1Ra synthesis suggest that the cir- 
1634  Interleukin 1 Receptor  Antagonist Induction by Acute Phase Proteins rhosis associated with c~I-AT deficiency may not be entirely 
due to inadequate  clearance of elastase  but also to reduced 
IL-1Ra synthesis. 
AGP is another hepatic APP implicated in the regulation 
of inflammation. AGP undergoes extensive posttranslational 
modification, including the acquisition of sialyl-Lewis-X con- 
taining glycans during an acute phase response (34). The ex- 
pression of the sialyl-Lewis-X epitope may allow AGP to bind 
to selectins present on leukocytes and endothelial cells. Such 
an interaction might interfere with leukocyte emigration and 
thereby suppress inflammation (34). Although AGP is known 
to  potentiate  LPS-induced  secretion  of  proinflammatory 
cytokines by human monocytes (25), it also induces the produc- 
tion of an IL-1 inhibitor by murine macrophages (35). The 
induction of this inhibitor appears to depend on the extent 
of glycosylation (35). Our studies strongly suggest that this 
IL-1 inhibitor is IL-1Ra. The AGP preparation used in our 
investigation was not as potent an inducer of IL-1Ra as CR.P 
or c~t-AT. However, we have not surveyed a wide range of 
AGP preparations,  in particular  material  isolated from sera 
of patients with inflammatory diseases. It is conceivable that 
the weak response to our AGP preparation could be due to 
inadequate  glycosylation. 
We have shown that three distinct, structurally unrelated 
APP are potent inducers of the antiinflammatory  cytokine 
IL-1Ra and have suggested that these inductive effects may 
account for some of their antiinflammatory properties. These 
same agents, however, are highly synergistic with low con- 
centrations of LPS in inducing the synthesis of both IL-I~ 
and IL-1Ra. In fact, the relative amounts of IL-1Ra and IL- 
18 generated in response to the APP/LPS combination are 
similar to those induced by high concentrations of LPS alone. 
These findings indicate that APP may function in a dual role, 
amplifying inflammatory responses when the inciting patho- 
gen is present within the host and down-modulating the re- 
sponse when the pathogen has been eradicated. Our results 
suggest that  modulation of the profile of cytokines gener- 
ated under different circumstances  may be the means by which 
such a dual function  is achieved. 
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